138 related articles for article (PubMed ID: 21308739)
1. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
[TBL] [Abstract][Full Text] [Related]
2. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Zulehner N; Maurer M; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
Gritsch D; Maurer M; Zulehner N; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):37-45. PubMed ID: 21275264
[TBL] [Abstract][Full Text] [Related]
5. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Wesierska-Gadek J; Borza A; Komina O; Maurer M
Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
[TBL] [Abstract][Full Text] [Related]
6. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Nair BC; Vallabhaneni S; Tekmal RR; Vadlamudi RK
Breast Cancer Res; 2011 Aug; 13(3):R80. PubMed ID: 21834972
[TBL] [Abstract][Full Text] [Related]
7. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Wesierska-Gadek J; Schmitz ML; Ranftler C
J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
[TBL] [Abstract][Full Text] [Related]
8. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
10. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
Maurer M; Komina O; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():250-6. PubMed ID: 19723062
[TBL] [Abstract][Full Text] [Related]
11. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
[TBL] [Abstract][Full Text] [Related]
12. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
Harrod A; Fulton J; Nguyen VTM; Periyasamy M; Ramos-Garcia L; Lai CF; Metodieva G; de Giorgio A; Williams RL; Santos DB; Gomez PJ; Lin ML; Metodiev MV; Stebbing J; Castellano L; Magnani L; Coombes RC; Buluwela L; Ali S
Oncogene; 2017 Apr; 36(16):2286-2296. PubMed ID: 27748765
[TBL] [Abstract][Full Text] [Related]
13. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
[TBL] [Abstract][Full Text] [Related]
15. Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.
Held JM; Britton DJ; Scott GK; Lee EL; Schilling B; Baldwin MA; Gibson BW; Benz CC
Mol Cancer Res; 2012 Aug; 10(8):1120-32. PubMed ID: 22669764
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression.
Weitsman GE; Li L; Skliris GP; Davie JR; Ung K; Niu Y; Curtis-Snell L; Tomes L; Watson PH; Murphy LC
Cancer Res; 2006 Oct; 66(20):10162-70. PubMed ID: 17047081
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
18. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
Komina O; Wesierska-Gadek J
Biochem Pharmacol; 2008 Dec; 76(11):1554-62. PubMed ID: 18761329
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Coker-Gurkan A; Arisan ED; Obakan P; Guvenir E; Unsal NP
Exp Cell Res; 2014 Oct; 328(1):87-98. PubMed ID: 25088259
[TBL] [Abstract][Full Text] [Related]
20. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
